^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Estybon (rigosertib) (PI3K inhibitor, PLK1 inhibitor, RAS antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
[The efficacy and side effects of rigosertib combined with chemotherapy in KRAS mutant colorectal cancer mice]
Published date:
02/01/2023
Excerpt:
55 days after administration, the fold change of tumor size of OXA+ RGS group was 37.019±8.634, which is significantly smaller than 77.571±15.387 of RGS group (P=0.029) and 92.500±13.279 of OXA group (P=0.008)….The combination of RGS and oxaliplatin has a stronger anti-tumor effect on KRAS mutant colorectal cancer.
DOI:
10.3760/cma.j.cn112152-20210514-00379
Source:
Title:
Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
Published date:
08/04/2021
Excerpt:
...in a KRAS-mutant, chemotherapy-resistant patient-derived xenograft model, RGS showed a stronger therapeutic effect than the combination standard therapy involving fluoropyrimidine + oxaliplatin/irinotecan + bevacizumab.
DOI:
10.20892/j.issn.2095-3941.2020.0532
Source:
Title:
470P - Anti-tumor mechanisms of rigosertib in colorectal cancer
Published date:
09/14/2020
Excerpt:
...anti-tumour effects of Rigosertib (RGS), either alone or in combination with 5-FU in colorectal cancer (CRC)....RGS inhibited cell proliferation and cell cycle progression in a Cell-type specific manner including SW480, Caco2, and CT-26 cell lines, and this was dependent on the presence of mutations in KRAS or its down-stream effectors.
Secondary therapy:
5-fluorouracil
Source:
Title:
/ 6 - Translational research of rigosertib, a small molecule RAS-mimetic for the treatment of RAS mutant colorectal cancer
Published date:
05/15/2020
Excerpt:
Preliminary analysis of this study showed that RGS has a definite inhibitory effect on RAS mutant colorectal cancer via inhibiting cell proliferation & inducing endogenous apoptosis.
